Dirven C M, Koudstaal J, Mooij J J, Molenaar W M
University Hospital, Vrije Universiteit, Department of Neurosurgery, Amsterdam, The Netherlands.
J Neurooncol. 1998 Mar;37(1):9-16. doi: 10.1023/a:1005905009449.
The proliferative potential of 39 pilocytic and 5 low grade astrocytomas was studied in relation to the Ki-67 activity as measured by the MIB-1 Labelings Index. The results were correlated to the biological behaviour of the tumor as measured by clinical and neuro-radiological (CT- or MRI-scans) follow-up of the patient. This study was undertaken to answer the question whether MIB-1 expression reflects differences in biological behaviour of these tumors, such as rapid progression of residual tumor or stable remaining tumor. MIB-1 LI values ranged from 0 to 19% in the group of pilocytic astrocytomas (mean 4.2%) and from 0 to 15% in the 5 low grade astrocytomas (mean 4,2%). All patients were operated and 23 of them had incomplete tumor resection as proven on postoperative neuro-imaging studies. Those 23 patients could be subdivided into two groups; one without progression of residual tumor during follow-up (n=12) and the other with tumor progression (n=11). mean MIB-1 LI in the group with 'quiescent' tumor tended to be lower than in the group with progressive tumor: 3,3% vs. 6,6%. Residual tumors which were negative for MIB-1 staining showed fewer progressions of residual tumor compared to those being positive for MIB-1 staining, however this difference was not significant (p=0, 15, Fisher exact test). Tumor samples of a second operation of the same patient had lower MIB-1 LI values than those of the samples taken at first operation. The proliferating potential seemed to be decreased after part of the tumor was resected. Pilocytic astrocytomas with a negative MIB-1 LI are unlikely to show progression of residual tumor after partial resection. MIB-1 staining might be an additional tool in determining the frequency and duration of follow-up and in making decisions regarding further treatment of a patient operated for a pilocytic astrocytoma with residual tumor.
通过MIB-1标记指数测量的Ki-67活性,研究了39例毛细胞型星形细胞瘤和5例低级别星形细胞瘤的增殖潜能。将结果与通过对患者进行临床和神经放射学(CT或MRI扫描)随访所测量的肿瘤生物学行为相关联。进行这项研究是为了回答MIB-1表达是否反映了这些肿瘤生物学行为的差异,例如残留肿瘤的快速进展或稳定残留。毛细胞型星形细胞瘤组的MIB-1 LI值范围为0至19%(平均4.2%),5例低级别星形细胞瘤组的MIB-1 LI值范围为0至15%(平均4.2%)。所有患者均接受了手术,其中23例术后神经影像学检查证实肿瘤切除不完全。这23例患者可分为两组;一组在随访期间残留肿瘤无进展(n = 12),另一组有肿瘤进展(n = 11)。“静止”肿瘤组的平均MIB-1 LI往往低于进展性肿瘤组:3.3%对6.6%。与MIB-1染色阳性的残留肿瘤相比,MIB-1染色阴性的残留肿瘤进展较少,然而这种差异不显著(p = 0.15,Fisher精确检验)。同一患者第二次手术的肿瘤样本的MIB-1 LI值低于第一次手术时采集的样本。部分肿瘤切除后,增殖潜能似乎降低。MIB-1 LI为阴性的毛细胞型星形细胞瘤在部分切除后不太可能出现残留肿瘤进展。MIB-1染色可能是确定随访频率和持续时间以及决定对患有残留肿瘤的毛细胞型星形细胞瘤患者进行进一步治疗的额外工具。